GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 180 Life Sciences Corp (NAS:ATNFW) » Definitions » Net Change in Cash

180 Life Sciences (180 Life Sciences) Net Change in Cash : $-1.97 Mil (TTM As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is 180 Life Sciences Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

180 Life Sciences's Net Change in Cash for the three months ended in Mar. 2024 was $-1.30 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.97 Mil.

180 Life Sciences Net Change in Cash Historical Data

The historical data trend for 180 Life Sciences's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

180 Life Sciences Net Change in Cash Chart

180 Life Sciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Net Change in Cash
-0.48 2.03 6.12 -1.25 -4.99

180 Life Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.32 -0.64 0.65 -0.69 -1.30

180 Life Sciences Net Change in Cash Calculation

180 Life Sciences's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-10.922+0+5.908+0.02
=-4.99

180 Life Sciences's Net Change in Cash for the quarter that ended in Mar. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-1.033+0+-0.264+-0.002
=-1.30

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.97 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

180 Life Sciences Net Change in Cash Related Terms

Thank you for viewing the detailed overview of 180 Life Sciences's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

180 Life Sciences (180 Life Sciences) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 180 Life Sciences Corp (NAS:ATNFW) » Definitions » Net Change in Cash
Comparable Companies
ENSC ADIL CWBR PHIO NBSE SLRX PBLA THAR ALLR NVIV OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
ATNF:USA
Address
3000 El Camino Real, Bldg. 4, Suite 200, Palo Alto, CA, USA, 94306
Website
https://www.180lifesciences.com
180 Life Sciences Corp is a clinical-stage biotechnology company. It is focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics.

180 Life Sciences (180 Life Sciences) Headlines

From GuruFocus

180 Life Sciences Corp. Announces $6.5 Million Registered Direct Offering

By PurpleRose PurpleRose • 07-18-2022

180 Life Sciences Provides Update on Progress To Seek Medicines and Healthcare Products Regulatory Agency Marketing Authorization for Anti-TNF Treatment of Early Stage Dupuytren's Contracture

By GlobeNewswire GlobeNewswire • 11-30-2022

180 Life Sciences Corp. Announces Closing of $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

By Tiesvg Tiesvg • 12-23-2022

180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Shareholders

By Tiesvg Tiesvg • 12-29-2022

180 Life Sciences with the University of Oxford Announce the Enrollment of the First Patient in a Trial of Anti-TNF for People with Early-Stage Frozen Shoulder

By PurpleRose PurpleRose • 08-22-2022

180�Life�Sciences Announces an Agreement for a Clinical Pharmacology Study Testing a New Formulation of CBD for Enhanced Oral Uptake

By Marketwired • 08-07-2023

180 Life Sciences to Participate in A.G.P.'s Virtual Biotech Conference to be Held November 30 � December 1, 2022

By Value_Insider Value_Insider • 11-21-2022

180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement

By Stock market mentor Stock market mentor • 01-05-2023

Newman Ferrara LLP Investigating Officers and Directors of 180 Life Sciences Corp. (ATNF)

By Business Wire Business Wire • 01-10-2023

180 Life Sciences Provides Update on Regulatory Approval Process in the UK and US for Dupuytren's Disease Treatment; Continues Consultations with the UK MHRA and Initiates a Type C Meeting Request With the US FDA

By Marketwired • 08-03-2023